Source comparison
Tesamorelin + Ipamorelin Blend: Research Application Comparison
Visceral Fat Reduction 15–20% at 26 weeks (2mg daily) 5–8% at 26 weeks (300mcg daily) 18–25% at 26 weeks (combined dosing) Tesamorelin drives the majority of visceral adipose reduction; Ipamorelin adds marginal direct lipolytic effect but amplifies GH pulse am
This comparison does not assign a generated winner or score.
- Visceral Fat Reduction
- 15–20% at 26 weeks (2mg daily)
- 5–8% at 26 weeks (300mcg daily)
- 18–25% at 26 weeks (combined dosing)
- Tesamorelin drives the majority of visceral adipose reduction; Ipamorelin adds marginal direct lipolytic effect but amplifies GH pulse amplitude when stacked
- Lean Mass Preservation
- Stable to +2% in lipodystrophy trials
- +3–5% in sarcopenia models (with training)
- +4–7% in recomposition protocols (with training)
- Synergistic anabolic signaling produces superior lean mass outcomes versus either peptide monotherapy
- Growth Hormone Peak (fold increase vs baseline)
- 2–3× baseline
- 2–4× baseline
- 4–6× baseline
- Dual pathway activation produces supra-additive GH peaks; magnitude depends on endogenous secretory capacity
- Cortisol Elevation Risk
- Minimal (GHRH pathway does not cross-activate ACTH)
- Minimal (GHSR-1a selective; no ACTH or prolactin activation)
- Minimal
- Both peptides avoid the cortisol spikes seen with non-selective secretagogues like GHRP-2 and GHRP-6
- Injection Frequency
- Once daily (before sleep)
- 1–2× daily (morning fasted + pre-sleep)
- Once daily (combined evening dose)
- Evening co-administration captures nocturnal GH pulse and minimizes injection burden versus split dosing
- Glycemic Impact
- Transient fasting glucose elevation in 10% of subjects; HbA1c +0.2–0.4%
- Minimal glucose effect at standard doses
- Similar to Tesamorelin alone; monitor in insulin-resistant populations
- GH's insulin-antagonistic effects are dose-dependent and most pronounced in subjects with baseline glucose intolerance